IREN proposes $875 million convertible notes offering due 2031
Zoetis Inc., a global leader in animal health with a market capitalization of $62 billion, saw its stock reach a 52-week low, closing at $139.67. According to InvestingPro data, the company maintains a solid financial health score and continues to deliver revenue growth of ~5.3% year-over-year. This milestone comes amid a challenging year for the company, with its stock experiencing a significant 1-year change of -28.23%. The decline reflects broader market trends and specific challenges within the animal health sector, as investors weigh the impact of economic conditions on the company’s performance. Despite trading at a P/E ratio of 24, InvestingPro analysis suggests the stock may be slightly undervalued at current levels. Despite the current low, Zoetis remains a key player in the industry, continuing to focus on innovation and growth strategies to navigate the evolving market landscape. The company maintains a healthy 1.41% dividend yield and demonstrates strong management commitment through share buybacks. Discover 10 more exclusive insights about Zoetis with InvestingPro’s comprehensive research report.
In other recent news, Zoetis Inc. reported second-quarter 2025 earnings that exceeded analysts’ expectations. The company achieved an earnings per share of $1.76, surpassing the forecasted $1.62, and its revenue reached $2.46 billion, higher than the anticipated $2.41 billion. Additionally, Zoetis announced a $1.85 billion senior notes offering, with maturities set for 2028 and 2035. The company has also entered a new five-year, $1.25 billion revolving credit facility, replacing a previous agreement set to expire in December 2027.
In regulatory developments, the European Medicines Agency’s Committee for Veterinary Medicinal Products issued a positive opinion for Zoetis’s cat osteoarthritis treatment, Portela, recommending marketing authorization. This treatment could become the first long-acting anti-nerve growth factor monoclonal antibody therapy for cats. Meanwhile, UBS adjusted its price target for Zoetis to $165 from $170, maintaining a Neutral rating after the company’s mixed second-quarter results. These updates reflect Zoetis’s recent strategic financial moves and product advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.